- Outlook Therapeutics press release ( NASDAQ: OTLK ): FY GAAP EPS of -$0.31 in-line.
- For the fiscal year ended Sept. 30, research and development expenses were $42.33M, compared to $38.96M in the prior year.
- As of Sept. 30, 2022, Outlook had cash and cash equivalents of $17.4M.
- "We are driving our commercialization planning towards expected launch with the accepted FDA filing of our BLA for ONS-5010 and PDUFA date set for August 29, 2023, and review of our MAA in the EU underway with a decision date expected in early 2024," said Outlook President and CEO C. Russell Trenary III.
- "We believe that ONS-5010 has the potential to be a game-changer for patients and physicians in the retina community, and we now have the necessary capital to support these efforts," Trenary III added.
For further details see:
Outlook Therapeutics GAAP EPS of -$0.31 in-line